Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer

Cancer Treatment Reviews

Volumn 41, Issue 5, 2015, Pages 401-411

  Califano, Raffaele ^a,b   Abidin, Aidalena ^a   Tariq, Noor ul Ain ^a   Economopoulou, Panagiota ^c   Metro, Giulio ^d   Mountzios, Giannis ^e  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

ALK; BRAF; DDR2; EGFR; HER2; KRA; Non small cell lung cancer; Oncogenic drivers; PI3KCA; ROS1

Indexed keywords

2 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 4 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO] 1,3,5 TRIAZINE; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BRIGATINIB; BRIVANIB; CABOZANTINIB; CARBOPLATIN; CERITINIB; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FICLATUZUMAB; FORETINIB; GEFITINIB; GOLVATINIB; ONARTUZUMAB; PACLITAXEL; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PILARALISIB; PLACEBO; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; SELUMETINIB; TIVANTINIB; TRAMETINIB; TRASTUZUMAB; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE;

ADVANCED CANCER; ASTHENIA; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME REARRANGEMENT; DDR2 GENE; DIARRHEA; DRUG TOLERABILITY; EGFR GENE; ENZYME INHIBITION; FATIGUE; FEVER; FGFR1 GENE; GENE MUTATION; HEADACHE; HER2 GENE; HUMAN; INSOMNIA; MET GENE; NAUSEA; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PI3KCA GENE; PNEUMONIA; RASH; RET GENE; REVIEW; ROS1 GENE; TREATMENT OUTCOME; VOMITING; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTO ONCOGENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84937512084     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.03.009     Document Type: Review

References (134)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics 2014. CA Cancer J Clin 2014, 64(1):9-29.
2. Johnson B.E., Kris M.G., Berry L.D., Kwiatkowski D.J., Iafrate A.J., Varella-Garcia M. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: the lung cancer mutation consortium (LCMC). J Clin Oncol 2013, 31. (suppl; abstr 8019).
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 May 20, 350(21):2129-2139.
4. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101(36):13306-13311.
5. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
6. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
7. Han J.Y., Park K., Kim S.W., Lee D.H., Kim H.Y., Kim H.T., et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30(10):1122-1128.
8. Inoue A., Kobayashi K., Maemondo M., Sugawara S., Oizumi S., Isobe H., et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013, 24(1):54-59.
9. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib monotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
10. Mitsudomi Tetsuya, Morita Satoshi, Yatabe Yasushi, Negoro Shunichi, Okamoto Isamu, Seto Takashi, et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol 2012, 30. (suppl; abstr 7521).
11. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutan, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
12. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8):735-742.
13. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-244.
14. Sequist L.V., Yang J.C., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31(27):3327-3334.
15. Wu Y.L., Zhou C., Hu C.P., Feng J., Lu S., Huang Y., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15(2):213-222.
16. Peters S., Adjei A.A., Gridelli C., Reck M., Kerr K., Felip E. ESMO, guidelines working group. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl. 7):56-64. vii56-64.
17. Keedy V.L., Temin S., Somerfield M.R., Beasley M.B., Johnson D.H., McShane L.M., et al. American society of clinical oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011, 29(15):2121-2127.
18. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
19. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., et al. Global survey of phosphotyrosine ulticentr identifies oncogenic kinases in lung cancer. Cell 2007, 131(6):1190-1203.
20. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703.
21. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13(10):1011-1019.
22. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368(25):2385-2394.
23. Mok T., Kim D.W., Wu Y.L., et al. First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients with advanced ALK-positive non-squamous non-small cell lung cancer: Results of a phase III study (PROFILE 1014). J Clin Oncol 2014, 32:5s. (suppl; abstr 8002).
24. Shaw A.T., Kim D.W., Mehra R., Tan D.S., Felip E., Chow L.Q., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370(13):1189-1197.
25. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7(4):295-308.
26. Roberts P.J., Stinchcombe T.E. KRAS mutation: should we test for it, and does it matter?. J Clin Oncol 2013, 31(8):1112-1121.
27. Dogan S., Shen R., Ang D.C., Johnson M.L., D' Angelo S.P., Paik P.K., et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012, 18(22):6169-6177.
28. Dearden S., Stevens J., Wu Y.L., Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013, 24(9):2371-2376.
29. Gainor J.F., Varghese A.M., Ou S.H., Kabraji S., Awad M.M., Katayama R., et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer. Clin Cancer Res 2013, 19(15):4273-4281.
30. Riely G.J., Kris M.G., Rosenbaum D., Marks J.L., Li A., Chitale D.A., et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008, 14(18):5731-5734.
31. Metro G., Chiari R., Duranti S., Siggillino A., Fischer M.J., Giannarelli D., et al. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer 2012, 78(1):81-86.
32. Califano R., Landi L., Cappuzzo F. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Drugs 2012, 19(72 Suppl. 1):28-36.
33. Jänne P.A., Shaw A.T., Pereira J.R., Jeannin G., Vansteenkiste J., Barrios C., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013, 14(1):38-47.
34. Bennouna J., Leighl N.B., Kelly K., Blumenschein G.T., Zalcman G., Audebert C., et al. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in a phase 1/1B trial involving KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): efficacy and biomarker results. J Thorac Oncol 2013, 8(Suppl. 2):2411. (abstract).
35. Mazieres J., Gandara S.R., Leighl N.B., Wheler J.J., Barlesi F., Zalcman G., et al. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed in a phase 1/1B trial involving KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): efficacy and biomarker results. J Thorac Oncol 2013, 8(Suppl. 2):2922. (abstract).
36. Blumenschein G.R., Smit E.F., Planchard D., Kim D.W., Cadranel J., De Pas T., et al. MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2013, 31. (suppl; abstr 8029).
37. Ihle N.T., Byers L.A., Kim E.S., Saintigny P., Lee J.J., Blumenschein G.R., et al. Effect of KRAS oncogene substitutions on protein ulticent: implications for ulticentr and clinical outcome. J Natl Cancer Inst 2012, 104(3):228-239.
38. Goldman J.W., Gandhi L., Patnaik A., Rosen L.S., Hilton J.F., Papadopoulos K.P., et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer. J Clin Oncol 2014, 32:5s. (suppl; abstr 8026).
39. Tolcher A.W., Khan K., Ong M., Banerji U., Papadimitrakopoulou V., Gandara D.R., et al. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res 2015, 21(4):739-748.
40. Gainor J.F., Shaw A.T. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 2013, 18(7):865-875.
41. Bergethon K., Shaw A.T., Ou S.H., Katayama R., Lovly C.M., McDonald N.T., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012, 30(8):863-870.
42. Warth A., Muley T., Dienemann H., Goeppert B., Stenzinger A., Schnabel P.A., et al. ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology 2014, 65(2):187-194.
43. Shaw A.T., Ou S.H., Bang Y.J., Camidge D.R., Solomon B.J., Salgia R., et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014, 371(21):1963-1971.
44. Johnson T.W., Richardson P.F., Bailey S., Brooun A., Burke B.J., Collins M.R., et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem 2014, 57(11):4720-4744.
45. Davare M.A., Saborowski A., Eide C.A., Tognon C., Smith R.L., Elferich J., et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci USA 2013, 110(48):19519-19524.
46. Awad M.M., Katayama R., McTigue M., Liu W., Deng Y.L., Brooun A., et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013, 368(25):2395-2401.
47. Shen L., Ji H.F. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370(26):2537.
48. Awad M.M., Shaw A.T. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014, 12:429-439.
49. Sang J., Acquaviva J., Friedland J.C., Smith D.L., Sequeira M., Zhang C., et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discovery 2013, 3(4):430-443.
50. Davies K.D., Mahale S., Astling D.P., Aisner D.L., Le A.T., Hinz T.K., et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS ONE 2013, 8(12):e82236.
51. Yi S., Tsao M.S. Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2000, 2(3):226-234.
52. Cooper C.S., Park M., Blair D.G., Tainsky M.A., Huebner K., Croce C.M., et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984, 311(5981):29-33.
53. Sadiq A.A., Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol 2013, 31(8):1089-1096.
54. Ichimura E., Maeshima A., Nakajima T., Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996, 87(10):1063-1069.
55. Nakamura Y., Niki T., Goto A., Morikawa T., Miyazawa K., Nakajima J., et al. C-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci 2007, 98(7):1006-1013.
56. Sequist L.V., von Pawel J., Garmey E.G., Akerley W.L., Brugger W., Ferrari D., et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011, 29(24):3307-3315.
57. Scagliotti G, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W et al. MARQUEE: A randomized, double-blind, placebo-controlled, phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small-cell lung cancer (NSCLC). In: European cancer congress 2013, abstr 3410.
58. Spigel D.R., Ervin T.J., Ramlau R.A., Daniel D.B., Goldschmidt J.H., Blumenschein G.R., et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013, 31(32):4105-4114.
59. Spigel D.R., Edelman M.J., O'Byrne K., Paz-Ares L., Shames D.S., et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, ulticentre, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 2014, 32:5s. (suppl; abstr 8000).
60. Camidge D.R., Ou S., Shapiro G., Otterson G.A., Villaruz L.C., Villalona-Calero M.A., et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 2014, 32:5s. (suppl; abstr 8001).
61. Hellerstedt B.A., Edelman G., Vogelzang N.J., Kluger H.M., Yasenchak C.A., Shen X., et al. Activity of cabozantinib (XL184) in metastatic NSCLC: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2012, 30. (suppl; abstr 7514).
62. Patnaik A., Weiss G.J., Papadopoulos K., Tibes R., Tolcher A.W., Payumo F.C., et al. Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (Mab), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J Clin Oncol 2010, 28:15s. (suppl; abstr 2525).
63. Mok T.S., Park K., Geater S.L., Agarwal S., Han M., Credi M., et al. A randomized phase (Ph) 2 study with exploratory biomarker analysis of ficlatuzumab (F) a humanized hepatocyte growth factor (HGF) inhibitory MAB in combination with gefitinib (G) versus G in Asian patients (pts) with lung adenocarcinoma (LA). Ann Oncol 2012, 23(Suppl. 9):ix391. (Abstract 1198P).
64. Mok T.S., Tan E., Greater S.L., Chang G., Yang J., Gyuris J., et al. Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic based subgroups of patients with previously untreated lung adenocarcinoma. Ann Oncol 2014, 25(Suppl. 4):58-84. (Abstract 205P).
65. Tran P., Gooding W.E., Villaruz L.C., Burns T.F., Socinski M.A., Tarhini A.A. Phase I study of rilotumumab (AMG 102), an HGF inhibitor, and erlotinib in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2014, 32. (suppl; abstr e19065).
66. Molife L.R., Dean E.J., Blanco-Codesido M., Krebs M.G., Brunetto A.T., Greystoke A.P., et al. A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors. Clin Cancer Res 2014, 20(24):6284-6294.
67. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., et al. A hierarchical network of inter receptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996, 16(10):5276-5287.
68. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244(4905):707-712.
69. Heinmöller P., Gross C., Beyser K., Schmidtgen C., Maass G., Pedrocchi M., et al. HER2 status in non-small cell lung cancer: results from patient screening for ulticent to a phase II study of ulticent. Clin Cancer Res 2003, 9(14):5238-5243.
70. Liu L., Shao X., Gao W., Bai J., Wang R., Huang P., et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 2010, 5(12):1922-1932.
71. Shigematsu H., Takahashi T., Nomura M., Majmudar K., Suzuki M., Lee H., et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005, 65(5):1642-1646.
72. Mazières J., Peters S., Lepage B., Cortot A.B., Barlesi F., Beau-Faller M., et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013, 31(16):1997-2003.
73. Tomizawa K., Suda K., Onozato R., Kosaka T., Endoh H., Sekido Y., et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 2011, 74(1):139-144.
74. Clamon G., Herndon J., Kern J., Govindan R., Garst J., Watson D., et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer 2005, 103(8):1670-1675.
75. Gatzemeier U., Groth G., Butts C., Van Zandwijk N., Shepherd F., Ardizzoni A., et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004, 15(1):19-27.
76. Lara P.N., Laptalo L., Longmate J., Lau D.H., Gandour-Edwards R., Gumerlock P.H., et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer 2004, 5(4):231-236.
77. Hirsch F.R., Franklin W.A., Veve R., Varella-Garcia M., Bunn P.A. HER2/neu expression in malignant lung tumors. Semin Oncol 2002, 29(1 Suppl. 4):51-58.
78. Cappuzzo F., Bemis L., Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006, 354(24):2619-2621.
79. Tomizawa K., Suda K., Onozato R., Kosaka T., Endoh H., Sekido Y., et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 2011, 74(1):139-144.
80. Ross H.J., Blumenschein G.R., Aisner J., Damjanov N., Dowlati A., Garst J., et al. Randomized phase II ulticentre trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 2010, 16(6):1938-1949.
81. De Grève J., Teugels E., Geers C., Decoster L., Galdermans D., De Mey J., et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012, 76(1):123-127.
82. Engelman J.A., Zejnullahu K., Gale C.M., Lifshits E., Gonzales A.J., Shimamura T., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007, 67(24):11924-11932.
83. Reckamp K.L., Giaccone G., Camidge D.R., Gadgeel S.M., Khuri F.R., Engelman J.A., et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 2014, 120(8):1145-1154.
84. Gandhi L., Bahleda R., Cleary J.M., Hollebecque A., Kwak E.L., Pandya S., et al. Two dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors. J Clin Oncol 2011, 29. (abstr 3027).
85. Besse B., Soria J., Yao B., Kris M., Chao B., Cortot A., et al. Neratinib (N) with or without temsirolimus (TEM) in patients (pts) with non small cell lung cancer (NSCLC) carrying HER2 somatic mutations: An international randomized phase II study. Ann Oncol 2014, 25(5):1-41. (Abstr LBA39_PR). 10.1093/annonc/mdu438.
86. Papin C., Denouel-Galy A., Laugier D., Calothy G., Eychène A. Modulation of kinase activity and oncogenic properties by alternative splicing reveals a novel regulatory mechanism for B-Raf. J Biol Chem 1998, 273(38):24939-24947.
87. Mason C.S., Springer C.J., Cooper R.G., Superti-Furga G., Marshall C.J., Marais R. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 1999, 18(8):2137-2148.
88. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
89. Sanchez-Torres J.M., Viteri S., Molina M.A., Rosell R. BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Transl Lung Cancer Res 2013, 2(3):244-250.
90. Marchetti A., Felicioni L., Malatesta S., Grazia Sciarrotta M., Guetti L., Chella A., et al. Clinical features and outcome of patients with non-small-cell lung cancer ulticentr BRAF mutations. J Clin Oncol 2011, 29(26):3574-3579.
91. Paik P.K., Arcila M.E., Fara M., Sima C.S., Miller V.A., Kris M.G., et al. Clinical characteristics of patients with lung adenocarcinomas ulticentr BRAF mutations. J Clin Oncol 2011, 29(15):2046-2051.
92. Pratilas C.A., Hanrahan A.J., Halilovic E., Persaud Y., Soh J., Chitale D., et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008, 68(22):9375-9383.
93. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26):2507-2516.
94. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380(9839):358-365.
95. Planchard D., Kim T.M., Mazieres J., Quoix E., Riely G.J., Barlesi F., et al. Dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): a ulticentre, open-label, phase II trial (BRF113928). Ann Oncol 2014, 25(Suppl. 5):v1-v41.
96. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12(2):175-180.
97. Ju Y.S., Lee W.C., Shin J.Y., Lee S., Bleazard T., Won J.K., et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012, 22(3):436-445.
98. Kohno T., Ichikawa H., Totoki Y., Yasuda K., Hiramoto M., Nammo T., et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012, 18(3):375-377.
99. Lipson D., Capelletti M., Yelensky R., Otto G., Parker A., Jarosz M., et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012, 18(3):382-384.
100. Takeuchi K., Soda M., Togashi Y., Suzuki R., Sakata S., Hatano S., et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012, 18(3):378-381.
101. D'Arcangelo M., D'Incecco A., Cappuzzo F. Rare mutations in non-small-cell lung cancer. Future Oncol 2013, 9(5):699-711.
102. Scagliotti G.V., Krzakowski M., Szczesna A., Strausz J., Makhson A., Reck M., et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012, 30(17):2070-2078.
103. Paz-Ares L.G., Biesma B., Heigener D., von Pawel J., Eisen T., Bennouna J., et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012, 30(25):3084-3092.
104. Morabito A., Piccirillo M.C., Costanzo R., Sandomenico C., Carillio G., Daniele G., et al. Vandetanib: an overview of its clinical development in NSCLC and other tumors. Drugs Today (Barc) 2010, 46(9):683-698.
105. Herbst R.S., Sun Y., Eberhardt W.E., Germonpré P., Saijo N., Zhou C., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11(7):619-626.
106. de Boer R.H., Arrieta Ó., Yang C.H., Gottfried M., Chan V., Raats J., et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011, 29(8):1067-1074.
107. Natale R.B., Thongprasert S., Greco F.A., Thomas M., Tsai C.M., Sunpaweravong P., et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011, 29(8):1059-1066.
108. Lee J.S., Hirsh V., Park K., Qin S., Blajman C.R., Perng R.P., et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012, 30(10):1114-1121.
109. Heymach J.V., Paz-Ares L., De Braud F., Sebastian M., Stewart D.J., Eberhardt W.E., et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008, 26(33):5407-5415.
110. Tsao A.S., Liu S., Lee J.J., Alden C.M., Blumenschein G.R., Herbst R., et al. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol 2013, 8(5):658-661.
111. Drilon A., Wang L., Hasanovic A., Suehara Y., Lipson D., Stephens P., et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discovery 2013, 3(6):630-635.
112. Drilon A., Rekhtman N., Ladanyi M., Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 2012, 13(10):e418-e426.
113. Behrens C., Lin H.Y., Lee J.J., Raso M.G., Hong W.K., Wistuba I.I., et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res 2008, 14(19):6014-6022.
114. Fischer H., Taylor N., Allerstorfer S., Grusch M., Sonvilla G., Holzmann K., et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 2008, 7(10):3408-3419.
115. Tran T.N., Selinger C.I., Kohonen-Corish M.R., McCaughan B.C., Kennedy C.W., et al. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer 2013, 81(3):462-467.
116. Weiss J., Sos M.L., Seidel D., Peifer M., Zander T., Heuckmann J.M., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010, 2(62). 62ra93.
117. Dutt A., Ramos A.H., Hammerman P.S., Mermel C., Cho J., Sharifnia T., et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE 2011, 6(6):e20351.
118. Gadgeel S.M., Chen W., Cote M.L., Bollig-Fischer A., Land S., Schwartz A.G., et al. Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR. PLoS ONE 2013 Nov 8, 8(11):e79820.
119. Ratain M.J., Schwartz H.G.K., Oza A.M., Rudin C.M., Kaye S.B., De Jonge M.J., et al. Brivanib (BMS-582664) in advanced solid tumors (AST): results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2011, 29. (suppl; abstr 3079).
120. Ji M., Guan H., Gao C., Shi B., Hou P. Highly frequent promoter methylation and PI3KCA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 2011, 20(11):147.
121. Kawano O., Sasaki H., Endo K., Suzuki E., Haneda H., Yukiue H., et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006, 54(2):209-215.
122. Yamamoto H., Shigematsu H., Nomura M., Lockwood W.W., Sato M., Okumura N., et al. PI3KCA mutations and copy number gains in human lung cancers. Cancer Res 2008, 68(17):6913-6921.
123. Spoerke J.M., O'Brien C., Huw L., Koeppen H., Fridlyand J., Brachmann R.K., et al. Phosphoinositide (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 2012, 18(24):6771-6783.
124. Zhang L., Shi L., Zhao X., Wang Y., Yue W. PI3KCA gene mutation associated with poor prognosis of lung adenocarcinoma. Onco Targets Ther 2013, 7(6):497-502.
125. Chaft J.E., Arcila M.E., Paik P.K., Lau C., Riely G.J., Pietanza M.C., et al. Coexistence of PI3KCA and other oncogene mutations in lung adenocarcinoma rationale for comprehensive mutation profiling. Mol Cancer Ther 2012, 11(2):485-491.
126. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75). (75ra26).
127. Ren H., Chen M., Yue P., Tao H., Owonikoko T.K., Ramalingam S.S., et al. The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer Lett 2012, 325(2):139-146.
128. Bendell J.C., Rodon J., Burris H.A., de Jonge M., Verweij J., Birle D., et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Clin Oncol 2012, 30(3):282-290.
129. Gonzalez Angulo A.M., Blumenschein G.R., et al. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 2013, 39(4):313-320.
130. Wagner A.J., Von Hoff D.H., LoRusso P.M., Tibes R., Mazina K.E., Ware J.A., et al. A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol 2009, 27:15s. (suppl; abstr 3501).
131. Sánchez V., Kuba M.G., Rinehart C., Arteaga C.L. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA 2012, 109(8):2718-2723.
132. Miao L., Wang Y., Zhu S., Shi M., Li Y., Ding J., et al. Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lungcancer of Chinese patients. BMC Cancer 2014, 24(14):369.
133. Hammerman P.S., Sos M.L., Ramos A.H., Xu C., Dutt A., Zhou W., et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery 2011, 1(1):78-89.
134. Sasaki H., Shitara M., Yokota K., Okuda K., Hikosaka Y., Moriyama S., et al. DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients. Oncol Lett 2012, 4(1):33-37.